These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 11747270)

  • 1. Minimal residual disease in gastrointestinal cancer.
    Kienle P; Koch M
    Semin Surg Oncol; 2001 Jun; 20(4):282-93. PubMed ID: 11747270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are "micrometastases" of the peritoneum equivalent to distant metastases?
    Kienle P; Koch M
    Dig Surg; 2002; 19(6):453-8. PubMed ID: 12499736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Minimal residual disease in gastrointestinal tumors: tumor detection in bone marrow, blood and lymph nodes].
    Rosenberg R; Nekarda H; Thorban S; Siewert JR
    Acta Med Austriaca Suppl; 2002; 59():42-53. PubMed ID: 12506760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer.
    Klein CA; Blankenstein TJ; Schmidt-Kittler O; Petronio M; Polzer B; Stoecklein NH; Riethmüller G
    Lancet; 2002 Aug; 360(9334):683-9. PubMed ID: 12241875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Technical aspects of minimal residual disease detection in carcinoma patients.
    Lacroix J; Doeberitz MK
    Semin Surg Oncol; 2001 Jun; 20(4):252-64. PubMed ID: 11747266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimal residual disease in thyroid carcinoma.
    Weber T; Klar E
    Semin Surg Oncol; 2001 Jun; 20(4):272-7. PubMed ID: 11747268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimal residual disease in non-small-cell lung cancer.
    Hosch SB; Scheunemann P; Izbicki JR
    Semin Surg Oncol; 2001 Jun; 20(4):278-81. PubMed ID: 11747269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection and characterization of residual disease in breast cancer.
    Pantel K; Felber E; Schlimok G
    J Hematother; 1994; 3(4):315-22. PubMed ID: 7735827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Minimal residual disease in solid cancer. Prognostic value and therapeutic consequences].
    Allgayer H; Heiss MM
    Fortschr Med Orig; 2001; 119(1):1-4. PubMed ID: 11935652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [R1 resection: their relevance to the surgery of gastrointestinal tumors].
    Jähne J
    Chirurg; 2007 Sep; 78(9):783-4. PubMed ID: 17671773
    [No Abstract]   [Full Text] [Related]  

  • 11. [Minimal residual tumor in gastrointestinal carcinoma. Relevance to prognosis and oncologic surgical consequences].
    Gretschel S; Bembenek A; Schulze T; Kemmner W; Schlag PM
    Chirurg; 2006 Dec; 77(12):1104-17. PubMed ID: 17119886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Micrometastases: marker of metastatic potential or evidence of residual disease?
    O'Sullivan GC; Collins JK; Kelly J; Morgan J; Madden M; Shanahan F
    Gut; 1997 Apr; 40(4):512-5. PubMed ID: 9176080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minimal residual disease in gastric cancer: evidence of an independent prognostic relevance of urokinase receptor expression by disseminated tumor cells in the bone marrow.
    Heiss MM; Simon EH; Beyer BC; Gruetzner KU; Tarabichi A; Babic R; Schildberg FW; Allgayer H
    J Clin Oncol; 2002 Apr; 20(8):2005-16. PubMed ID: 11956259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. pTNM and residual tumor classifications: problems of assessment and prognostic significance.
    Hermanek P
    World J Surg; 1995; 19(2):184-90. PubMed ID: 7754621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A new approach for discovering minimal residual disease in patients with operable breast cancer].
    Iovchev I; Trifonov D; Nikolov S; Lazarov N; Dimitrov G
    Khirurgiia (Sofiia); 2003; 59(3):19-22. PubMed ID: 15584457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic impact of disseminated tumor cells and microRNA-17-92 cluster deregulation in gastrointestinal cancer.
    Valladares-Ayerbes M; Blanco M; Haz M; Medina V; Iglesias-Díaz P; Lorenzo-Patiño MJ; Reboredo M; Santamarina I; Figueroa A; Antón-Aparicio LM; Calvo L
    Int J Oncol; 2011 Nov; 39(5):1253-64. PubMed ID: 21743960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical relevance of minimal residual disease monitoring in non-Hodgkin's lymphomas: a critical reappraisal of molecular strategies.
    Corradini P; Ladetto M; Pileri A; Tarella C
    Leukemia; 1999 Nov; 13(11):1691-5. PubMed ID: 10557040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical implications of the EGF receptor/ligand system for tumor progression and survival in gastrointestinal carcinomas: evidence for new therapeutic options.
    Kopp R; Rothbauer E; Ruge M; Arnholdt H; Spranger J; Muders M; Pfeiffer DG; Schildberg FW; Pfeiffer A
    Recent Results Cancer Res; 2003; 162():115-32. PubMed ID: 12790326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of molecular biological and immunohistological parameters in gastrointestinal carcinomas.
    Rüschoff J; Bocker T; Vogel P; Schlegel J
    Recent Results Cancer Res; 1996; 142():73-88. PubMed ID: 8893336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunocytochemical and molecular strategies for the detection of micrometastases in patients with solid epithelial tumours: a review.
    Pantel K; Ahr A
    Nucl Med Commun; 1998 Jun; 19(6):521-7. PubMed ID: 10234655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.